Hiba Musbah, a 36-year-old mother of three in Deir el-Balah, has endured seven rounds of chemotherapy for breast cancer while waiting approximately two years for Israeli security clearance to leave Gaza for further treatment. Her surgery was delayed two months by military operations around Nasser Hospital in Khan Younis. Her chemotherapy was delayed seven months by medicine shortages. She now cannot afford the 150-shekel ($48) CT scan she needs to determine whether the cancer has spread, and the waiting list for one exceeds three months. She cannot walk properly and has lost function in one arm. The structural picture is worse than any individual case. Gaza recorded roughly 360 new breast cancer cases annually before the war, dropping to 250 in 2024 and about 260 in 2025 — not because incidence fell, but because the screening and diagnostic apparatus collapsed. Mammography machines have repeatedly broken down. Laboratory supplies are scarce. Chemotherapy, hormonal therapy, and targeted therapies are unavailable or critically low. Radiotherapy is completely absent. Surgery for advanced tumours has been halted due to the lack of specialised capabilities. Dr. Iman al-Haj Ahmad, an obstetrician-gynaecologist diagnosed with breast cancer in May 2025, illustrates the double bind. A medical professional with connections struggled to find a functioning mammogram. She waited about a month for surgery, eventually operated on by a visiting Jordanian team at Nasser Hospital under dangerous conditions. Chemotherapy combined with severe food shortages caused her to lose 20 kilograms and forced doctors to pause her treatment. Her referral for radiotherapy abroad has been pending since September 2025. She continues to examine other women and refer suspected cases despite her own deteriorating health. The evacuation pipeline — coordinated between the WHO and Gaza's Ministry of Health, then submitted to Israel for security screening — is the single chokepoint controlling access to treatment that does not exist inside Gaza. Musbah has been in this queue for two years with no explanation for the delay. The process converts a medical emergency into an indefinite administrative limbo, with Israel holding unilateral veto power over who exits. Health workers at Hekr al-Jameh Health Centre in Deir el-Balah have screened 700 to 800 women during a Pink October campaign, identifying seven or eight cases requiring further assessment. But identification without treatment capacity creates a cruel paradox: women learn they likely have cancer, then face the same broken referral chain. Free mammography exists at a limited number of hospitals with long waits. Private screening is prohibitively expensive for families already displaced and impoverished. The war's death toll has exceeded 74,400 Palestinians. Within that catastrophe, cancer patients occupy a particularly trapped position — their disease progresses on a biological clock that the blockade, the destroyed infrastructure, and the security-screening bottleneck all ignore. Delayed diagnosis means later-stage detection. Later-stage detection means more aggressive treatment needed. More aggressive treatment is precisely what Gaza cannot provide. The feedback loop is self-reinforcing. Mushah's case crystallises the mechanism: a treatable disease rendered potentially fatal not by medical complexity but by systematic destruction of the health system and control over movement. She wants to travel, receive treatment, recover, and return to caring for her children. The obstacle is not medical science. It is the architecture of the blockade.
